Cargando…

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors

Triple-negative breast cancer (TNBC) is a type of breast tumor that currently lacks options for targeted therapy. Tremendous effort has been made to identify treatment targets for TNBC. Here, we report that the expression level of anaphase promoting complex (APC) coactivator Cdh1 in TNBC is elevated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junjun, Lan, Mengjiao, Peng, Jin, Xiong, Qunli, Xu, Yongfeng, Yang, Yang, Zhou, Ying, Liu, Jinlu, Zeng, Zhu, Yang, Xiaojuan, Zhang, Zhiwei, Zhang, Pumin, Zhu, Qing, Wu, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141497/ https://www.ncbi.nlm.nih.gov/pubmed/35627188 http://dx.doi.org/10.3390/genes13050803

Ejemplares similares

Serum Nardilysin as a Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
por: Xu, Yongfeng, et al.
Publicado: (2022)

KRAS Gene Copy Number as a Negative Predictive Biomarker for the Treatment of Metastatic Rectal Cancer With Cetuximab: A Case Report
por: Xiong, Qunli, et al.
Publicado: (2022)

Krüppel-like Factor 6 Suppresses the Progression of Pancreatic Cancer by Upregulating Activating Transcription Factor 3
por: Xiong, Qunli, et al.
Publicado: (2022)

The deubiquitinase USP28 maintains the expression of the transcription factor MYCN and is essential in neuroblastoma cells
por: Li, Junjun, et al.
Publicado: (2023)

The function of APC/C(Cdh1 )in cell cycle and beyond
por: Li, Min, et al.
Publicado: (2009)

The dual role of p63 in cancer
por: Xu, Yongfeng, et al.
Publicado: (2023)

Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer
por: Xiong, Qunli, et al.
Publicado: (2022)

Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
por: Singh, Desh Deepak, et al.
Publicado: (2021)

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma
por: Zhang, Zhiwei, et al.
Publicado: (2023)

DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors()
por: Shi, Yaqin, et al.
Publicado: (2019)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

Small Non-Coding RNAs in Human Cancer
por: Xiong, Qunli, et al.
Publicado: (2022)

NSD3, a member of nuclear receptor‐binding SET domain family, is a potential prognostic biomarker for pancreatic cancer
por: Xiong, Qunli, et al.
Publicado: (2023)

Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies
por: Labrie, Marilyne, et al.
Publicado: (2021)

Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: A case report
por: Gomez-Puerto, Diego, et al.
Publicado: (2022)

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC
por: Zhang, Mi, et al.
Publicado: (2022)

The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency
por: Gu, Yayun, et al.
Publicado: (2021)

Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
por: Zhang, Mengqi, et al.
Publicado: (2023)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
por: Aguilar-Quesada, Rocío, et al.
Publicado: (2007)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

Transcription-Replication Collisions and Chromosome Fragility
por: Wu, Wei, et al.
Publicado: (2021)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

Extracellular ATP promotes angiogenesis and adhesion of TNBC cells to endothelial cells via upregulation of CTGF
por: Zhou, Yan‐Ting, et al.
Publicado: (2022)

ATAD5 deficiency alters DNA damage metabolism and sensitizes cells to PARP inhibition
por: Giovannini, Sara, et al.
Publicado: (2020)

Model for predicting immunotherapy based on M2 macrophage infiltration in TNBC
por: Wu, Haoming, et al.
Publicado: (2023)

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
por: Guan, Xiaolin, et al.
Publicado: (2022)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

CDK5 Inhibition Abrogates TNBC Stem‐Cell Property and Enhances Anti‐PD‐1 Therapy
por: Bei, Yuncheng, et al.
Publicado: (2020)

Epigenetic regulation of CDH1 exon 8 alternative splicing in gastric cancer
por: Li, Xiao-Wei, et al.
Publicado: (2015)

Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
por: Wang, Panpan, et al.
Publicado: (2020)

Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents
por: Póti, Ádám, et al.
Publicado: (2019)

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
por: Sulaiman, Andrew, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dap3iagonbi9dmltq3for591u3